IP Verse

Enhancement Of Tumor Response To Chemotherapy By Activation Of The Asmase/Ceramide Pathway Through Timed Administration Of A Short-Acting Anti-Angiogenic Agent

Patent No. EP3217983 (titled "Enhancement Of Tumor Response To Chemotherapy By Activation Of The Asmase/Ceramide Pathway Through Timed Administration Of A Short-Acting Anti-Angiogenic Agent") was filed by Memorial Sloan Kettering Cancer Center on Nov 12, 2015. The application was issued on May 1, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HAMM & WITTKOPPJan 31, 2025HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3217983

MEMORIAL SLOAN KETTERING CANCER CENTER
Application Number
EP15859462A
Filing Date
Nov 12, 2015
Status
Granted And Under Opposition
Mar 29, 2024
Publication Date
May 1, 2024
External Links
Slate, Register , Google Patents